DKNG Stock Analysis: DraftKings | NASDAQ
Gambling | NASDAQ, USA | Market Cap: 9.413m USD | 12M Return: -45.5% | US26142V1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 295M
Qual. Beats: -2
Rev. Trend: 98.5%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.3 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
DraftKings Inc. (NASDAQ: DKNG) is a digital sports entertainment and gaming company headquartered in Boston, Massachusetts, and founded in 2011. The company went public on April 24, 2020, and is classified within the Consumer Discretionary sector under the Casinos & Gaming sub-industry, with a large-cap market capitalization of approximately $10.9 billion USD.
DraftKings operates a diversified online gaming platform spanning online and retail sports betting, daily fantasy sports, digital lottery courier services, prediction markets, and iGaming products such as blackjack, roulette, baccarat, and slot machines. The company also licenses proprietary sports betting and casino gaming software to third-party operators. Its business model is anchored in the U.S. digital sports betting and iGaming markets, which expanded following the 2018 Supreme Court decision striking down PASPA and have since become among the fastest-growing segments within the broader gaming industry. DraftKings generates revenue primarily through player wagering activity, with contributions from marketing partnerships, platform licensing, and brand integrations across professional sports leagues.
- New state sports betting legalization expands US TAM
- iGaming revenue scales with higher margins than sportsbook
- Promotional spend pressures profitability against FanDuel competition
| Net Income: -378.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -7.19 > 1.0 |
| NWC/Revenue: -0.38% < 20% (prev 3.09%; Δ -3.47% < -1%) |
| CFO/TA 0.08 > 3% & CFO 383.5m > Net Income -378.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (496.9m) vs 12m ago -6.15% < -2% |
| Gross Margin: 40.45% > 18% (prev 39.23%; Δ 1.22% > 0.5%) |
| Asset Turnover: 138.8% > 50% (prev 118.0%; Δ 20.72% > 0%) |
| Interest Coverage Ratio: -11.79 > 6 (EBIT TTM -353.6m / Interest Expense TTM 30.0m) |
| A: -0.01 (Total Current Assets 1.89b - Total Current Liabilities 1.92b) / Total Assets 4.61b |
| B: -1.51 (Retained Earnings -6.95b / Total Assets 4.61b) |
| C: -0.08 (EBIT TTM -353.6m / Avg Total Assets 4.62b) |
| D: 0.04 (Book Value of Equity 179.6m / Total Liabilities 4.43b) |
| Altman-Z'' = -5.42 = D |
| DSRI: 1.31 (Receivables 100.4m/65.6m, Revenue 6.41b/5.46b) |
| GMI: 0.97 (GM 39.23% / 40.45%) |
| AQI: 1.00 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 1.17 (Revenue 6.41b / 5.46b) |
| TATA: -0.17 (NI -378.8m - CFO 383.5m) / TA 4.61b) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of November 21, 2026, the stock is trading at USD 15.80 with a total of 15,178,085 shares traded. Over the past week, the price has changed by -16.36%, over one month by -22.85%, over three months by -36.88% and over the past year by -45.52%.
Current recommended Stop Loss: 14.10 (which is 10.8% or 1.4 ATR below the current price).
DraftKings has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy DKNG.
- StrongBuy: 22
- Buy: 4
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 26.4 | 67.1% |
P/E Forward = 11.4811
P/S = 1.469
P/B = 53.0368
P/EG = 0.0515
Revenue TTM = 6.41b USD
EBIT TTM = -353.6m USD
EBITDA TTM = -50.3m USD
Long Term Debt = 2.19b USD (from longTermDebt, last quarter)
Short Term Debt = 8.76m USD (from shortTermDebt, last quarter)
Debt = 2.37b USD (from shortLongTermDebtTotal, last quarter) + Leases 89.7m
Net Debt = 1.27b USD (calculated: Debt 2.37b - CCE 1.10b)
Enterprise Value = 10.7b USD (9.41b + Debt 2.37b - CCE 1.10b)
Interest Coverage Ratio = -11.79 (Ebit TTM -353.6m / Interest Expense TTM 30.0m)
EV/FCF = 37.40x (Enterprise Value 10.7b / FCF TTM 285.7m)
FCF Yield = 2.67% (FCF TTM 285.7m / Enterprise Value 10.7b)
FCF Margin = 4.46% (FCF TTM 285.7m / Revenue TTM 6.41b)
Net Margin = -5.91% (Net Income TTM -378.8m / Revenue TTM 6.41b)
Gross Margin = 40.45% ((Revenue TTM 6.41b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 32.28% (prev 38.21%)
Tobins Q-Ratio = 2.32 (Enterprise Value 10.7b / Total Assets 4.61b)
Interest Expense / Debt = 1.26% (Interest Expense 30.0m / Debt 2.37b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -279.4m (EBIT -353.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.99 (Total Current Assets 1.89b / Total Current Liabilities 1.92b)
Debt / Equity = 13.21 (Debt 2.37b / totalStockholderEquity, last quarter 179.6m)
Debt / EBITDA = -25.31 (negative EBITDA) (Net Debt 1.27b / EBITDA -50.3m)
Debt / FCF = 4.45 (Net Debt 1.27b / FCF TTM 285.7m)
Total Stockholder Equity = 496.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.20% (Net Income -378.8m / Total Assets 4.61b)
RoE = -76.32% (Net Income TTM -378.8m / Total Stockholder Equity 496.4m)
RoCE = -13.15% (EBIT -353.6m / Capital Employed (Equity 496.4m + L.T.Debt 2.19b))
RoIC = -11.72% (negative operating profit) (NOPAT -279.4m / Invested Capital 2.38b)
WACC = 6.57% (E(9.41b)/V(11.8b) * Re(7.98%) + D(2.37b)/V(11.8b) * Rd(1.26%) * (1-Tc(0.21)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.75 | Cagr: 1.62%
[DCF] Terminal Value 73.10% ; FCFF base≈419.0m ; Y1≈367.5m ; Y5≈296.9m
[DCF] Fair Price = 7.01 (EV 4.77b - Net Debt 1.27b = Equity 3.49b / Shares 498.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.61 | # QB: -2
Revenue Correlation: 98.52 | Revenue CAGR: 22.45% | SUE: -1.24 | # QB: -2
EPS current Quarter (2027-03-31): EPS=0.01 | Chg30d=-96.01% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.50 | Chg30d=-44.49% | Revisions=+0% | GrowthEPS=-24.5% | GrowthRev=+7.0%
EPS next Year (2027-12-31): EPS=1.37 | Chg30d=-19.38% | Revisions=+22% | GrowthEPS=+174.2% | GrowthRev=+16.5%
[Analyst] Revisions Ratio: +8% (up=5, down=4)